ACTU Actuate Therapeutics | $0.99 -2.0% | 7/30/2026 | | Initiated Coverage | $6.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Actuate Therapeutics (NASDAQ:ACTU) on 7/30/2026 |
ZNTL Zentalis Pharmaceuticals | $3.70 +3.9% | 7/23/2026 | | Initiated Coverage | $11.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Zentalis Pharmaceuticals (NASDAQ:ZNTL) on 7/23/2026 |
ELDN Eledon Pharmaceuticals | $3.58 +1.1% | 7/21/2026 | | Initiated Coverage | $12.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Eledon Pharmaceuticals (NASDAQ:ELDN) on 7/21/2026 |
ELDN Eledon Pharmaceuticals | $3.58 +1.1% | 7/21/2026 | | Initiated Coverage | $12.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Eledon Pharmaceuticals (NASDAQ:ELDN) on 7/21/2026 |
ATOS Atossa Genetics | $2.79 +7.3% | 7/7/2026 | | Initiated Coverage | $12.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Atossa Genetics (NASDAQ:ATOS) on 7/7/2026 |
VTVT vTv Therapeutics | $31.31 +4.0% | 6/30/2026 | | Initiated Coverage | $67.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of vTv Therapeutics (NASDAQ:VTVT) on 6/30/2026 |
ELTX Elicio Therapeutics | $3.02 -2.3% | 6/15/2026 | | Reiterated Rating | | Buy | 00.00% | View details for Rodman & Renshaw rating of Elicio Therapeutics (NASDAQ:ELTX) on 6/15/2026 |
KYNB Kyntra Bio | $6.81 -3.4% | 6/9/2026 | | Initiated Coverage | $30.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Kyntra Bio (NASDAQ:KYNB) on 6/9/2026 |
NGNE Neurogene | $36.68 +1.5% | 6/3/2026 | | Initiated Coverage | $70.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Neurogene (NASDAQ:NGNE) on 6/3/2026 |
NGNE Neurogene | $36.68 +1.5% | 6/3/2026 | | Upgrade | $70.00 | Strong-Buy | 00.00% | View details for Rodman & Renshaw rating of Neurogene (NASDAQ:NGNE) on 6/3/2026 |
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
|
SABS SAB Biotherapeutics | $3.77 +1.9% | 5/11/2026 | | Reiterated Rating | $13.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of SAB Biotherapeutics (NASDAQ:SABS) on 5/11/2026 |
SANA Sana Biotechnology | $3.68 +3.7% | 5/11/2026 | | Initiated Coverage | $16.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Sana Biotechnology (NASDAQ:SANA) on 5/11/2026 |
ABNB Airbnb | $179.29 -2.6% | 5/4/2026 | | Initiated Coverage | | Buy | 00.00% | View details for Rodman & Renshaw rating of Airbnb (NASDAQ:ABNB) on 5/4/2026 |
AVXL Anavex Life Sciences | $3.21 -0.3% | 5/4/2026 | | Initiated Coverage | $20.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Anavex Life Sciences (NASDAQ:AVXL) on 5/4/2026 |
HURA TuHURA Biosciences | $2.28 -7.7% | 4/15/2026 | | Initiated Coverage | | Buy | 00.00% | View details for Rodman & Renshaw rating of TuHURA Biosciences (NASDAQ:HURA) on 4/15/2026 |
CAMP CAMP4 Therapeutics | $5.00 -8.1% | 4/14/2026 | | Initiated Coverage | $7.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of CAMP4 Therapeutics (NASDAQ:CAMP) on 4/14/2026 |
CAMP CAMP4 Therapeutics | $5.00 -8.1% | 4/14/2026 | | Initiated Coverage | $7.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of CAMP4 Therapeutics (NASDAQ:CAMP) on 4/14/2026 |
SABS SAB Biotherapeutics | $3.77 +1.9% | 4/2/2026 | | Initiated Coverage | $13.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of SAB Biotherapeutics (NASDAQ:SABS) on 4/2/2026 |
ENTA Enanta Pharmaceuticals | $12.83 -2.5% | 3/26/2026 | | Initiated Coverage | $20.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Enanta Pharmaceuticals (NASDAQ:ENTA) on 3/26/2026 |
SGMT Sagimet Biosciences | $10.43 -1.1% | 3/26/2026 | | Initiated Coverage | $28.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Sagimet Biosciences (NASDAQ:SGMT) on 3/26/2026 |
BTAI BioXcel Therapeutics | $0.89 -25.2% | 3/17/2026 | | Initiated Coverage | $17.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of BioXcel Therapeutics (NASDAQ:BTAI) on 3/17/2026 |
ELTX Elicio Therapeutics | $3.02 -2.3% | 3/10/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Rodman & Renshaw rating of Elicio Therapeutics (NASDAQ:ELTX) on 3/10/2026 |
KPTI Karyopharm Therapeutics | $1.81 -10.4% | 3/10/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Rodman & Renshaw rating of Karyopharm Therapeutics (NASDAQ:KPTI) on 3/10/2026 |
ELTX Elicio Therapeutics | $3.02 -2.3% | 3/9/2026 | | Initiated Coverage | $17.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Elicio Therapeutics (NASDAQ:ELTX) on 3/9/2026 |
KPTI Karyopharm Therapeutics | $1.81 -10.4% | 3/9/2026 | | Initiated Coverage | $28.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Karyopharm Therapeutics (NASDAQ:KPTI) on 3/9/2026 |
MIRA MIRA Pharmaceuticals | $0.79 +1.3% | 1/13/2026 | | Initiated Coverage | | Buy | 00.00% | View details for Rodman & Renshaw rating of MIRA Pharmaceuticals (NASDAQ:MIRA) on 1/13/2026 |
TELO Telomir Pharmaceuticals | $1.06 -2.8% | 1/13/2026 | | Initiated Coverage | | Buy | 00.00% | View details for Rodman & Renshaw rating of Telomir Pharmaceuticals (NASDAQ:TELO) on 1/13/2026 |
AAPG Ascentage Pharma Group International | $18.20 -4.2% | 1/13/2026 | | Initiated Coverage | $48.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Ascentage Pharma Group International (NASDAQ:AAPG) on 1/13/2026 |
BMEA Biomea Fusion | $1.35 +2.3% | 1/13/2026 | | Initiated Coverage | $8.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Biomea Fusion (NASDAQ:BMEA) on 1/13/2026 |
JSPR Jasper Therapeutics | $0.84 +6.6% | 1/13/2026 | | Initiated Coverage | $17.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Jasper Therapeutics (NASDAQ:JSPR) on 1/13/2026 |
BTAI BioXcel Therapeutics | $0.89 -25.2% | 3/19/2025 | | Initiated Coverage | $65.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of BioXcel Therapeutics (NASDAQ:BTAI) on 3/19/2025 |
BTAI BioXcel Therapeutics | $0.89 -25.2% | 3/19/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Rodman & Renshaw rating of BioXcel Therapeutics (NASDAQ:BTAI) on 3/19/2025 |
TELO Telomir Pharmaceuticals | $1.06 -2.8% | 2/21/2025 | | Initiated Coverage | $15.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Telomir Pharmaceuticals (NASDAQ:TELO) on 2/21/2025 |
TELO Telomir Pharmaceuticals | $1.06 -2.8% | 2/20/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Rodman & Renshaw rating of Telomir Pharmaceuticals (NASDAQ:TELO) on 2/20/2025 |
CRDL Cardiol Therapeutics | $1.80
| 1/28/2025 | | Initiated Coverage | $7.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Cardiol Therapeutics (NASDAQ:CRDL) on 1/28/2025 |
CRDL Cardiol Therapeutics | $1.80
| 1/28/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Rodman & Renshaw rating of Cardiol Therapeutics (NASDAQ:CRDL) on 1/28/2025 |
INDV Indivior | $39.08 +0.2% | 1/28/2025 | | Initiated Coverage | $16.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Indivior (NASDAQ:INDV) on 1/28/2025 |
INDV Indivior | $39.08 +0.2% | 1/28/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Rodman & Renshaw rating of Indivior (NASDAQ:INDV) on 1/28/2025 |
INMB INmune Bio | $2.13 -1.8% | 1/28/2025 | | Initiated Coverage | $23.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of INmune Bio (NASDAQ:INMB) on 1/28/2025 |
INMB INmune Bio | $2.13 -1.8% | 1/28/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Rodman & Renshaw rating of INmune Bio (NASDAQ:INMB) on 1/28/2025 |
The cat is out the bag (Ad) Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day.
Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits. Watch Porter Stansberry's full investigation into the Final Displacement now |
PYPD PolyPid | $4.77 +0.6% | 1/28/2025 | | Initiated Coverage | $13.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of PolyPid (NASDAQ:PYPD) on 1/28/2025 |
PYPD PolyPid | $4.77 +0.6% | 1/28/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Rodman & Renshaw rating of PolyPid (NASDAQ:PYPD) on 1/28/2025 |
TLPH Talphera | $1.20 -2.4% | 1/28/2025 | | Initiated Coverage | $4.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Talphera (NASDAQ:TLPH) on 1/28/2025 |
TLPH Talphera | $1.20 -2.4% | 1/28/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Rodman & Renshaw rating of Talphera (NASDAQ:TLPH) on 1/28/2025 |
ATRA Atara Biotherapeutics | $8.36 +3.3% | 1/21/2025 | | Downgrade | | Strong-Buy ➝ Hold | 00.00% | View details for Rodman & Renshaw rating of Atara Biotherapeutics (NASDAQ:ATRA) on 1/21/2025 |
ATRA Atara Biotherapeutics | $8.36 +3.3% | 12/20/2024 | | Initiated Coverage | $25.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Atara Biotherapeutics (NASDAQ:ATRA) on 12/20/2024 |
ATRA Atara Biotherapeutics | $8.36 +3.3% | 12/20/2024 | | Upgrade | | Strong-Buy | 00.00% | View details for Rodman & Renshaw rating of Atara Biotherapeutics (NASDAQ:ATRA) on 12/20/2024 |
HURA TuHURA Biosciences | $2.28 -7.7% | 12/19/2024 | | Initiated Coverage | $11.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of TuHURA Biosciences (NASDAQ:HURA) on 12/19/2024 |
HURA TuHURA Biosciences | $2.28 -7.7% | 12/19/2024 | | Upgrade | | Strong-Buy | 00.00% | View details for Rodman & Renshaw rating of TuHURA Biosciences (NASDAQ:HURA) on 12/19/2024 |
THAR Tharimmune | $2.02 +2.5% | 12/6/2024 | | Initiated Coverage | $17.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Tharimmune (NASDAQ:THAR) on 12/6/2024 |
THAR Tharimmune | $2.02 +2.5% | 12/6/2024 | | Upgrade | | Strong-Buy | 00.00% | View details for Rodman & Renshaw rating of Tharimmune (NASDAQ:THAR) on 12/6/2024 |
ACHV Achieve Life Sciences | $7.50 -1.2% | 11/14/2024 | | Initiated Coverage | $12.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Achieve Life Sciences (NASDAQ:ACHV) on 11/14/2024 |
ACHV Achieve Life Sciences | $7.50 -1.2% | 11/14/2024 | | Upgrade | | Strong-Buy | 00.00% | View details for Rodman & Renshaw rating of Achieve Life Sciences (NASDAQ:ACHV) on 11/14/2024 |
ADIL Adial Pharmaceuticals | $4.99 +25.4% | 11/14/2024 | | Initiated Coverage | $200.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Adial Pharmaceuticals (NASDAQ:ADIL) on 11/14/2024 |
ADIL Adial Pharmaceuticals | $4.99 +25.4% | 11/14/2024 | | Upgrade | | Strong-Buy | 00.00% | View details for Rodman & Renshaw rating of Adial Pharmaceuticals (NASDAQ:ADIL) on 11/14/2024 |
EPRX Eupraxia Pharmaceuticals | $6.82 +1.5% | 11/14/2024 | | Initiated Coverage | $9.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Eupraxia Pharmaceuticals (NASDAQ:EPRX) on 11/14/2024 |
EPRX Eupraxia Pharmaceuticals | $6.82 +1.5% | 11/14/2024 | | Upgrade | | Strong-Buy | 00.00% | View details for Rodman & Renshaw rating of Eupraxia Pharmaceuticals (NASDAQ:EPRX) on 11/14/2024 |
OMER Omeros | $17.36 +1.0% | 11/14/2024 | | Initiated Coverage | $9.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Omeros (NASDAQ:OMER) on 11/14/2024 |
OMER Omeros | $17.36 +1.0% | 11/14/2024 | | Upgrade | | Strong-Buy | 00.00% | View details for Rodman & Renshaw rating of Omeros (NASDAQ:OMER) on 11/14/2024 |
RMTI Rockwell Medical | $7.49 +1.1% | 11/14/2024 | | Initiated Coverage | $50.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Rockwell Medical (NASDAQ:RMTI) on 11/14/2024 |
RMTI Rockwell Medical | $7.49 +1.1% | 11/14/2024 | | Upgrade | | Strong-Buy | 00.00% | View details for Rodman & Renshaw rating of Rockwell Medical (NASDAQ:RMTI) on 11/14/2024 |
BCAX Bicara Therapeutics | $24.94 +2.7% | 11/5/2024 | | Initiated Coverage | $48.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Bicara Therapeutics (NASDAQ:BCAX) on 11/5/2024 |
BCAX Bicara Therapeutics | $24.94 +2.7% | 11/5/2024 | | Upgrade | | Strong-Buy | 00.00% | View details for Rodman & Renshaw rating of Bicara Therapeutics (NASDAQ:BCAX) on 11/5/2024 |
QNCX Quince Therapeutics | $34.12 +0.2% | 10/29/2024 | | Initiated Coverage | $2,200.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Quince Therapeutics (NASDAQ:QNCX) on 10/29/2024 |
QNCX Quince Therapeutics | $34.12 +0.2% | 10/29/2024 | | Upgrade | | Strong-Buy | 00.00% | View details for Rodman & Renshaw rating of Quince Therapeutics (NASDAQ:QNCX) on 10/29/2024 |
ANRO Alto Neuroscience | $33.70 +4.9% | 10/23/2024 | | Downgrade | | Buy ➝ Neutral | 00.00% | View details for Rodman & Renshaw rating of Alto Neuroscience (NYSE:ANRO) on 10/23/2024 |
MNPR Monopar Therapeutics | $116.49 +3.1% | 10/11/2024 | | Initiated Coverage | $50.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Monopar Therapeutics (NASDAQ:MNPR) on 10/11/2024 |
KYTX Kyverna Therapeutics | $8.95 +9.5% | 10/9/2024 | | Initiated Coverage | $16.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Kyverna Therapeutics (NASDAQ:KYTX) on 10/9/2024 |
KYTX Kyverna Therapeutics | $8.95 +9.5% | 10/9/2024 | | Upgrade | | Strong-Buy | 00.00% | View details for Rodman & Renshaw rating of Kyverna Therapeutics (NASDAQ:KYTX) on 10/9/2024 |
NKTX Nkarta | $2.43 +4.3% | 10/9/2024 | | Initiated Coverage | $14.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Nkarta (NASDAQ:NKTX) on 10/9/2024 |
NKTX Nkarta | $2.43 +4.3% | 10/9/2024 | | Upgrade | | Strong-Buy | 00.00% | View details for Rodman & Renshaw rating of Nkarta (NASDAQ:NKTX) on 10/9/2024 |
MIRA MIRA Pharmaceuticals | $0.79 +1.3% | 9/30/2024 | | Initiated Coverage | $17.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of MIRA Pharmaceuticals (NASDAQ:MIRA) on 9/30/2024 |
MIRA MIRA Pharmaceuticals | $0.79 +1.3% | 9/30/2024 | | Upgrade | | Strong-Buy | 00.00% | View details for Rodman & Renshaw rating of MIRA Pharmaceuticals (NASDAQ:MIRA) on 9/30/2024 |
BMEA Biomea Fusion | $1.35 +2.3% | 9/26/2024 | | Upgrade | $18.00 | Neutral ➝ Buy | 00.00% | View details for Rodman & Renshaw rating of Biomea Fusion (NASDAQ:BMEA) on 9/26/2024 |
EBS Emergent Biosolutions | $4.49 -2.2% | 9/13/2024 | | Reiterated Rating | $16.00 ➝ $16.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Emergent Biosolutions (NYSE:EBS) on 9/13/2024 |
LONA Athira Pharma | $7.71 -3.3% | 9/4/2024 | | Downgrade | | Buy ➝ Neutral | 00.00% | View details for Rodman & Renshaw rating of Athira Pharma (NASDAQ:LONA) on 9/4/2024 |
PASG Passage Bio | $4.54 -1.1% | 9/3/2024 | | Initiated Coverage | $140.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Passage Bio (NASDAQ:PASG) on 9/3/2024 |
CRMD CorMedix | $7.67 +1.7% | 8/26/2024 | | Initiated Coverage | $13.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of CorMedix (NASDAQ:CRMD) on 8/26/2024 |
DERM Journey Medical | $6.46 -3.9% | 8/22/2024 | | Initiated Coverage | $9.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Journey Medical (NASDAQ:DERM) on 8/22/2024 |
EBS Emergent Biosolutions | $4.49 -2.2% | 8/22/2024 | | Initiated Coverage | $16.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Emergent Biosolutions (NYSE:EBS) on 8/22/2024 |
MIST Milestone Pharmaceuticals | $1.10
| 8/22/2024 | | Initiated Coverage | $9.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Milestone Pharmaceuticals (NASDAQ:MIST) on 8/22/2024 |
LONA Athira Pharma | $7.71 -3.3% | 8/19/2024 | | Initiated Coverage | $220.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Athira Pharma (NASDAQ:LONA) on 8/19/2024 |
FLNA Cassava Sciences | $0.89 -2.6% | 8/8/2024 | | Reiterated Rating | $107.00 ➝ $107.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Cassava Sciences (NASDAQ:FLNA) on 8/8/2024 |
IPSC Century Therapeutics | $1.95 +1.6% | 8/8/2024 | | Initiated Coverage | $6.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Century Therapeutics (NASDAQ:IPSC) on 8/8/2024 |
CRSP CRISPR Therapeutics | $54.28 +1.4% | 8/2/2024 | | Initiated Coverage | $90.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of CRISPR Therapeutics (NASDAQ:CRSP) on 8/2/2024 |
ANVS Annovis Bio | $1.76 -4.9% | 7/2/2024 | | Reiterated Rating | $67.00 ➝ $67.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Annovis Bio (NYSE:ANVS) on 7/2/2024 |
CGTX Cognition Therapeutics | $1.02 +1.0% | 7/2/2024 | | Reiterated Rating | $14.00 ➝ $14.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Cognition Therapeutics (NASDAQ:CGTX) on 7/2/2024 |
CYPH Cypherpunk Technologies | $0.71 +9.5% | 6/28/2024 | | Initiated Coverage | $8.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Cypherpunk Technologies (NASDAQ:CYPH) on 6/28/2024 |
NKTR Nektar Therapeutics | $72.67 -0.5% | 6/28/2024 | | Initiated Coverage | $30.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Nektar Therapeutics (NASDAQ:NKTR) on 6/28/2024 |
SANA Sana Biotechnology | $3.68 +3.7% | 6/26/2024 | | Initiated Coverage | $16.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Sana Biotechnology (NASDAQ:SANA) on 6/26/2024 |
The retirement stock I'd buy before Nvidia today (Ad) In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Chaikin Money Flow indicator has a new top retirement pick.
The company holds three fast-growing businesses -- including an autonomous vehicle unit and a streaming service with 10x Netflix's reach -- any of which could be spun off in the next 12 to 24 months. It also pays a dividend, a rarity among high-growth AI names.
Chaikin lays out the full case in a new free presentation, no email or credit card required. Get Marc Chaikin's free presentation on this overlooked AI stock now |
ANRO Alto Neuroscience | $33.70 +4.9% | 6/21/2024 | | Initiated Coverage | $43.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Alto Neuroscience (NYSE:ANRO) on 6/21/2024 |
COYA Coya Therapeutics | $4.67 -2.5% | 6/13/2024 | | Initiated Coverage | $18.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Coya Therapeutics (NASDAQ:COYA) on 6/13/2024 |
HRTX Heron Therapeutics | $0.32 -5.0% | 6/13/2024 | | Initiated Coverage | $7.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Heron Therapeutics (NASDAQ:HRTX) on 6/13/2024 |
MNKD MannKind | $3.90 +1.3% | 6/13/2024 | | Initiated Coverage | $8.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of MannKind (NASDAQ:MNKD) on 6/13/2024 |
RANI Rani Therapeutics | $0.80 0.0% | 6/13/2024 | | Initiated Coverage | $10.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Rani Therapeutics (NASDAQ:RANI) on 6/13/2024 |
SCLX Scilex | $6.40 -5.3% | 6/13/2024 | | Initiated Coverage | $455.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Scilex (NASDAQ:SCLX) on 6/13/2024 |
TRVI Trevi Therapeutics | $18.48 +0.1% | 6/13/2024 | | Initiated Coverage | $7.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Trevi Therapeutics (NASDAQ:TRVI) on 6/13/2024 |
ANVS Annovis Bio | $1.76 -4.9% | 6/4/2024 | | Initiated Coverage | $67.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of Annovis Bio (NYSE:ANVS) on 6/4/2024 |
BHC Bausch Health Cos | $6.57 +0.9% | 8/10/2017 | | Reiterated Rating | $17.00 | Neutral | 00.00% | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 8/10/2017 |
CRMD CorMedix | $7.67 +1.7% | 8/10/2017 | | Lower Price Target | $25.00 ➝ $15.00 | Buy | 00.00% | View details for Rodman & Renshaw rating of CorMedix (NASDAQ:CRMD) on 8/10/2017 |